OrbiMed Advisors
http://www.orbimed.com/OrbiMed is the world's largest healthcare-dedicated investment firm, with approximately $5 billion in assets under management. The firm was stated in 1989 with a vision to invest across the spectrum of healthcare companies: from private start-ups to large multinational companies.
View Older Stories View More Recent Stories
-
Emergence Therapeutics raises €87 million Series A financing to advance Nectin-4 ADC
-
Odyssey Therapeutics Announces $218 Million Series A Financing to Advance Next Generation Inflammation and Oncology Medicines
-
Emergence Therapeutics raises €87 million Series A financing to advance Nectin-4 ADC
-
Cyrus Biotechnology Announces $18M Financing and Acquisition of Orthogonal Biologics to Form an Integrated Software-Driven Pre-Clinical-Stage Drug Discovery Firm
-
Form SC 13D/A Theseus Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A Acutus Medical, Inc. Filed by: ORBIMED ADVISORS LLC
-
Form 4 Tricida, Inc. For: Nov 15 Filed by: ORBIMED ADVISORS LLC
-
Alpheus Medical CLOSES $16M IN Series A Financing for novel glioma BRAIN cancer treatment
-
Form 13F-HR ORBIMED ADVISORS LLC For: Sep 30
-
Form SC 13D/A ALPINE IMMUNE SCIENCES, Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A Compass Therapeutics, Filed by: ORBIMED ADVISORS LLC
-
Form 4 Compass Therapeutics, For: Nov 04 Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A Sierra Oncology, Inc. Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A Corvus Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A Repare Therapeutics Inc. Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D Theseus Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC
-
Form SC 13G/A Kala Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A SYNLOGIC, INC. Filed by: ORBIMED ADVISORS LLC
-
Form 4 Corvus Pharmaceuticals, For: Sep 20 Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A Corvus Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC
-
i2020 Accelerator Announces the Launch of Gwynant Therapeutics and Celyn Therapeutics to Develop Novel Small Molecules for Oncology Targets
-
iECURE Launches With $50 Million Series A Financing to Develop In Vivo Gene Insertion Approaches for Devastating Diseases
-
ADARx Raises $75 Million to Advance Growing Pipeline
-
Form SC 13D/A Aadi Bioscience, Inc. Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A BELLUS Health Inc. Filed by: ORBIMED ADVISORS LLC
-
Form 4 Repare Therapeutics Inc. For: Aug 31 Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A Acutus Medical, Inc. Filed by: ORBIMED ADVISORS LLC
-
Form 4 Repare Therapeutics Inc. For: Aug 26 Filed by: ORBIMED ADVISORS LLC
-
Neurogastrx Secures $60 Million in Series B Financing and Expands Management Team to Advance Its Pipeline of Transformative Investigational Therapies for Gastrointestinal Disorders
-
Form 4 Repare Therapeutics Inc. For: Aug 23 Filed by: ORBIMED ADVISORS LLC
-
Form 4 Repare Therapeutics Inc. For: Aug 17 Filed by: ORBIMED ADVISORS LLC
-
Form 4 Xtant Medical Holdings, For: Aug 15 Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A Ikena Oncology, Inc. Filed by: ORBIMED ADVISORS LLC
-
Form 13F-HR ORBIMED ADVISORS LLC For: Jun 30
-
Form SC 13D/A Oric Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A Corvus Pharmaceuticals, Filed by: ORBIMED ADVISORS LLC
-
XinThera Closes $50M Series B Financing
-
Zentera Therapeutics Announces Closing of $75 Million Series B Financing
-
Zentera Therapeutics Announces Closing of $75 Million Series B Financing
-
Form 4/A IMARA Inc. For: Jul 16 Filed by: ORBIMED ADVISORS LLC
-
Form 4 Acutus Medical, Inc. For: Jul 19 Filed by: ORBIMED ADVISORS LLC
-
Form 4 IMARA Inc. For: Jul 16 Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A Compass Therapeutics, Filed by: ORBIMED ADVISORS LLC
-
Form SC 13D/A Acutus Medical, Inc. Filed by: ORBIMED ADVISORS LLC
-
Form 4 SpringWorks Therapeutics For: Jul 01 Filed by: ORBIMED ADVISORS LLC
-
Form 4 SpringWorks Therapeutics For: Jun 28 Filed by: ORBIMED ADVISORS LLC
-
Form 4 SpringWorks Therapeutics For: Jun 23 Filed by: ORBIMED ADVISORS LLC
-
Leukocare Announces USD 17.5 Million Financing Round to Further Expand US Business and Bioinformatics Activities
-
Form SC 13D Janux Therapeutics, Inc. Filed by: ORBIMED ADVISORS LLC
-
Frontera Therapeutics Starts GMP Manufacturing Facility Construction

